AbCellera Biologics Inc vs Avantis US Small Cap Value ETF — how do they compare? AbCellera Biologics Inc trades at $8.92 (market cap $2.85B), while Avantis US Small Cap Value ETF trades at $127.9. Which is the better fit depends on your goals.
| ABCL | AVUV | |
|---|---|---|
Market Cap | $2.85B | — |
Sector | Health | Sector/Thematic |
52-Week High | $9.76 | $128.74 |
52-Week Low | $2.78 | $93.93 |
Enterprise Value | $2.45B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
AVUV trades at $126.88, up 0.36% today, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights strong small-cap value performance and potential benefits from rate outlook shifts. The ETF focuses on U.S. small-cap value stocks, offering diversification from tech-heavy portfolios.
Outlook remains positive due to small-cap momentum and value factor tailwinds, but risks include higher volatility and sensitivity to interest rates. Analyst sentiment is favorable, emphasizing long-term growth potential in tax-advantaged accounts like Roth IRAs.
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →